Member-only story
#6 — The Transformative Impact of a New Cancer Drug: A Case Study of Toripalimab and its 30X cost in the US
With the recent approval of Chinese cancer drug Toripalimab by the FDA (Food and Drug Administration) in the United States, it marks a great next step in the fight against cancer. The work that the Chinese researchers have done in medical science is remarkable with the accomplishment and the release of this drug globally. Though there are challenges ahead as it relates to its (30X) cost and accessibility in the US markets.
Cancer, a disease of uncontrolled growth of abnormal cells in the body, remains one of the most leading causes of unnatural death around the world. The development of these Cancer drugs take us one step closer to helping fight this disease, gives hope to millions of patients and in many cases, helps in improving survival rates, slowing the progression of the disease and helping enhance the quality of life for patients fighting this illness.
Toripalimab: The drug is called the “beacon of hope” for patients, particularly in treating those with rare and hard to treat cancers. The effectiveness of this drug is high in terms of fighting the cancer cells by empowering the body’s immune system similar to other immunotherapy treatments available in the market.
